Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an announcement.
Shanghai Fosun Pharmaceutical announced that its subsidiary, Jinzhou Avanc Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the drug registration of Fovinaciclib Citrate Capsules. This new drug is intended for use in combination with Fulvestrant to treat adult patients with hormone receptor-positive and HER2-negative recurrent or metastatic breast cancer, marking a significant step in the company’s oncology portfolio and potentially enhancing its market position in cancer treatment solutions.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company incorporated in China, operating in the pharmaceutical industry. The company focuses on the development and manufacturing of pharmaceuticals, with a market emphasis on innovative drug solutions.
Average Trading Volume: 4,628,611
Technical Sentiment Signal: Hold
Current Market Cap: HK$62.5B
See more insights into 2196 stock on TipRanks’ Stock Analysis page.